Circulogene (Formerly Known As Circulogene Theranostics)
3125 Independence Drive, Suite 301
19 articles with Circulogene (Formerly Known As Circulogene Theranostics)
CIRCULOGENE Announces Issuance of U.S. Patent for Method of Preparing Cell-Free Nucleic Acid Molecules by In Situ Amplification
Issued patent recognizes CIRCULOGENE’s novel method of enriching cfDNA without DNA isolation, extraction or purification, enabling “in situ” genetic manipulation of biofluid samples
CIRCULOGENE – Subcontractor to U.S. Department of Defense Research Award – to Develop Liquid Biopsy Markers for Traumatic Brain Injury
$1.5 Million grant to The Geneva Foundation will use CIRCULOGENE’s liquid biopsy to quickly ID and accurately quantify organ-specific injury markers for improved treatment and survival in severely wounded military and civilian personnel
CIRCULOGENE, advancing precision medicine through personalized molecular genetics testing, will be presenting three abstracts at the 2019 American Association for Cancer Research (AACR) Annual Meeting, March 29 - April 3, 2019, at the Georgia World Congress Center in Atlanta.
CIRCULOGENE, advancing precision medicine through molecular genetics testing, has named Anthony L. Schmidt, M.D., F.A.C.P., as Medical Director.
CIRCULOGENE Molecular Diagnostics Laboratory Receives College of American Pathologists (CAP) Accreditation
CIRCULOGENE announced that its molecular diagnostics laboratory has received College of American Pathologists accreditation based on a recent on-site inspection as part of CAP’s Accreditation Programs.
Proprietary, cfRNA-enriched, real-time PCR testing rapidly identifies all patients with NTRK fusion-positive cancers potentially eligible for new TRK inhibitor targeted therapy
Enables paired somatic-germline testing, broadens targeted treatment population for breast, ovarian, pancreatic and prostate cancers.
CIRCULOGENE’s Molecular Testing Can Potentially Improve Management of Advanced Ovarian Cancer Patients
Independent UAB study demonstrates potential value of company’s molecular testing in noninvasive, serial tracking of genomic changes in treatment-resistant ovarian cancer
CIRCULOGENE is accepting grant applications for a cancer research sample testing pilot program.
CIRCULOGENE Announces International Licensing of Proprietary Molecular Diagnostics Testing Technology to Turkey-Based Laboratory
Under terms of the agreement, CIRCULOGENE’s low-volume, high-yield, extraction-free and loss-free sample preparation coupled with next-generation sequencing technology is being licensed to CIRCULOGENE Saglik of Istanbul, Turkey.
11/29/2017Dr. Weiss will oversee and advance the laboratory’s research efforts and further educate oncologists about CIRCULOGENE’s next-generation sequencing (NGS) technology.
CIRCULOGENE Introduces Single-Tube, Blood-Based Microsatellite Instability (MSI) Biomarker Testing for Multiple Cancers
The advanced immunotherapy testing is immediately available to oncologists and pathologists, enabling them to identify patients eligible for treatment with Keytruda (pembrolizumab) across multiple cancer types, or Opdivo (nivolumab) for colorectal cancer.
Circulogene Expands Liquid Biopsy Testing Capabilities, Adds Three cfRNA-based NSCLC Tests Supporting Personalized Treatment for Lung Cancer Patients
New Research Involving Circulogene Theranostics’s Liquid Biopsy Further Validates Test’s Cancer Mutation Detection Capabilities
AACR 2016 Research Shows Circulogene Theranostics Liquid Biopsy Excels At Real-Time Monitoring Of Cancer Mutations
Circulogene Theranostics Liquid Biopsy Research Accepted For Abstract Presentation At AACR Annual Meeting